Written Question·Department of Health and Social Care·UIN 64682
Prostate Cancer: Hormone Treatments
Tabled: 2 July 2025
Answered: 15 July 2025
Question
Danny Beales
Labour — Uxbridge and South Ruislip
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of NHS England’s decision not to commission abiraterone acetate plus prednisone/prednisolone for men with high risk non metastatic prostate cance
Answer
Karin SmythNHS England develops an Equality and Health Inequalities Impact Assessment (EHIA) for policy propositions included in its Policy Work Programme. The EHIA for abiraterone acetate plus prednisone for hormone sensitive non-metastatic prostate cancer noted th...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 64682) →